A review and opinion piece in The Lancet, led by researchers at UCL and UCLH, raises the question of whether blood transfusions can inadvertently pass on harmful brain proteins - and whether extra precautionary safety measures should be considered while the science is still being worked out. The protein at the centre of the discussion is amyloid-beta, which is linked both to Alzheimer's disease and to cerebral amyloid angiopathy (CAA), a condition in which amyloid deposits in blood vessel walls lead to bleeding strokes.
The strongest signal the authors point to comes from a large Scandinavian epidemiological study published in 2023. It found that people who received blood from donors who later went on to develop multiple brain bleeds - a marker of CAA - had a higher risk of brain bleeds themselves. The authors are explicit that this pattern does not establish cause and effect. It does, however, sit uncomfortably enough to warrant serious follow-up on whether amyloid-beta pathology, and CAA along with it, could travel through the blood supply.
Professor John Collinge, who led the work, framed the issue in terms of maintaining confidence in a treatment that already works. Blood transfusions save many lives, he said, and precisely because they are so important, any potential risk deserves thorough investigation. That is a very different message from telling patients to worry about transfusions they have had or may need.
For now this is a call for research and for a hard look at whether current safeguards are sufficient, not a finding that transfusions cause Alzheimer's disease or CAA. The practical value of the piece lies in prompting blood services and researchers to examine the question directly rather than waiting for the answer to emerge from epidemiology alone.